List of Excipients in Branded Drug CUBICIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	CUBICIN	daptomycin	67919-011	SODIUM HYDROXIDE
Merck Sharp & Dohme LLC	CUBICIN RF	daptomycin	67919-012	SODIUM HYDROXIDE
Merck Sharp & Dohme LLC	CUBICIN RF	daptomycin	67919-012	SUCROSE

CUBICIN Excipient Strategy and Commercial Opportunities for Daptomycin Injection

Last updated: August 2, 2026

CUBICIN is an injectable daptomycin product whose commercial differentiation depends less on novel excipients than on formulation execution, hospital workflow, reconstitution stability, packaging, and generic manufacturing economics. The branded product uses a simple lyophilized formulation containing daptomycin, sucrose, and sodium hydroxide. That simplicity limits conventional excipient patent opportunities but creates openings for ready-to-use presentations, improved stability, reduced preparation time, lower waste, and differentiated delivery systems.

The main commercial opportunity is no longer protection of the original CUBICIN formulation. It is development of hospital-use alternatives that reduce compounding labor, support outpatient parenteral antimicrobial therapy, improve container closure and cold-chain performance, or provide a regulatory pathway for differentiated daptomycin products.

What excipients are used in CUBICIN?

CUBICIN contains daptomycin as the active ingredient and uses sucrose and sodium hydroxide as inactive ingredients. The product is supplied as a sterile, preservative-free, lyophilized powder for intravenous administration.[1]

Product attribute	CUBICIN formulation
Active ingredient	Daptomycin
Dosage form	Lyophilized powder for injection
Strengths	350 mg and 500 mg vials
Primary bulking or stabilizing excipient	Sucrose
pH adjustment	Sodium hydroxide
Preservative	None
Reconstitution diluent	0.9% sodium chloride injection
Administration	Intravenous infusion or injection, depending on label instructions
Storage before reconstitution	Refrigerated storage
Key formulation issue	Stability after reconstitution and dilution

Sucrose is primarily a lyoprotectant and bulking agent. It helps preserve the protein-like cyclic lipopeptide during freeze-drying and supports cake structure. Sodium hydroxide adjusts formulation pH. The formulation does not rely on surfactants, antimicrobial preservatives, complex buffering systems, or multiple stabilizer classes.

That narrow excipient profile is important for generic development. A manufacturer does not need to reproduce every inactive ingredient quantitatively, but it must demonstrate pharmaceutical equivalence, comparable quality attributes, and suitability for the applicable abbreviated new drug application pathway.[2]

Why was sucrose selected for daptomycin injection?

Sucrose is commercially attractive because it is familiar to regulators, widely available, inexpensive, and compatible with sterile lyophilized products. It can reduce aggregation and structural damage during freezing and drying without creating the same formulation complexity associated with surfactants or amino-acid stabilizer systems.

For CUBICIN, the excipient strategy supports four product requirements:

1. Preservation of daptomycin during lyophilization.
2. Rapid reconstitution in normal saline.
3. Acceptable chemical and physical stability after reconstitution.
4. Compatibility with hospital intravenous administration.

The limited formulation also reduces risks associated with excipient-mediated toxicity, extractables, particulate formation, and injection-site tolerability. This is useful in hospital settings where products are prepared by pharmacy staff and administered to medically complex patients.

The tradeoff is that sucrose does not solve all stability and handling problems. Commercial developers must assess aggregation, subvisible particles, potency loss, container adsorption, reconstitution time, foam generation, and stability under diluted conditions. These attributes can create differentiation even when the qualitative excipient list remains similar.

What formulations are protected by CUBICIN’s original product strategy?

The original CUBICIN commercial formulation is a sterile lyophilized daptomycin powder in a single-dose vial. Its competitive position historically came from the approved product, manufacturing know-how, clinical data, branded hospital adoption, and regulatory exclusivity rather than from a complex excipient platform.

Publicly available FDA labeling identifies sucrose and sodium hydroxide but does not establish that each formulation parameter is independently patent-protected.[1] Patent scope must be evaluated claim by claim across composition, manufacturing, stability, dosage, treatment method, and container systems.

The most commercially relevant formulation claim categories are:

• Lyophilized daptomycin compositions.
• Daptomycin stabilized with carbohydrate excipients.
• Defined pH ranges.
• Reconstitution and dilution conditions.
• Stable liquid or ready-to-use daptomycin compositions.
• Container closure systems that limit moisture or oxygen exposure.
• Manufacturing processes for producing a consistent sterile cake.
• Methods of treating complicated skin and skin-structure infections and bacteremia.

A developer should separate expired core daptomycin composition rights from later patents covering specific presentations or methods. A simple excipient substitution does not automatically avoid a patent claim if the claim covers a functional formulation range or a combination of excipients.

When did CUBICIN lose exclusivity?

CUBICIN’s principal small-molecule and regulatory exclusivity periods have expired or have been overtaken by generic competition. Daptomycin was approved by FDA in 2003, and generic daptomycin products entered the U.S. market after patent and litigation barriers were resolved.[3]

Exclusivity category	CUBICIN status
New chemical entity exclusivity	Expired
Original formulation exclusivity	Expired
Orphan-drug exclusivity for applicable indication	Expired
Patent-based generic barrier	Largely expired or resolved
Current product status	Generic competition in the U.S.
Biosimilar pathway	Not applicable
Primary commercial issue	Price erosion and hospital contracting

The exact launch date for a particular generic depends on the applicant, dosage strength, litigation outcome, settlement terms, and FDA approval timing. Orange Book listings and FDA approval records remain the controlling sources for product-specific status.[2,3]

What is the Orange Book status of CUBICIN?

CUBICIN is an FDA-approved small-molecule injectable listed under NDA 021572. The Orange Book is relevant for identifying listed patents, patent-use codes, exclusivity, and approved reference-product information.[2]

A review of CUBICIN’s Orange Book position should address:

• Whether any patent remains listed for the specific strength.
• Whether the patent claims the active ingredient, formulation, method of use, or manufacturing process.
• Whether a listed method-of-use patent is relevant to the proposed label.
• Whether an ANDA applicant filed a Paragraph IV certification.
• Whether the reference sponsor filed a timely infringement action.
• Whether any 30-month stay or settlement restriction affected launch.

Because CUBICIN is an established injectable product with generic versions, the commercial value of any remaining patent claim is likely to depend on narrow product attributes rather than broad daptomycin exclusivity.

What Paragraph IV challenges affected CUBICIN?

Generic applicants historically challenged CUBICIN-related patents through Paragraph IV certifications. The relevant litigation involved generic versions of daptomycin for injection and disputes over patent validity, enforceability, infringement, and the scope of treatment claims.

The key litigation questions for a current developer are not simply whether a historical Paragraph IV case existed. They are:

• Whether the patent was invalidated, expired, or disclaimed.
• Whether a settlement granted an authorized launch date.
• Whether the claim covers all daptomycin injection products or only a specific indication.
• Whether a later formulation patent remains enforceable.
• Whether the applicant’s proposed labeling carves out patented uses.
• Whether the product is vulnerable to an injunction or only damages exposure.

For a new excipient-based product, a freedom-to-operate review should cover both expired CUBICIN patents and later patents held by generic manufacturers, contract manufacturers, or formulation developers. Generic entry can create secondary patent activity around ready-to-use bags, concentrated solutions, vial adapters, reconstitution devices, and stability-enhancing compositions.

How strong is the CUBICIN patent estate?

The original CUBICIN patent estate is commercially weaker than it was before generic entry because the broad product opportunity has matured and multiple manufacturers have developed daptomycin injection products. The remaining value is more likely to reside in narrow claims involving formulation performance, manufacturing controls, packaging, or specific clinical use.

Patent estate component	Current strategic strength
Broad daptomycin composition claims	Low after expiry
Basic lyophilized injectable product	Low to moderate, depending on claim status
Sucrose-based formulation claims	Limited unless narrowly defined and unexpired
Ready-to-use liquid formulation	Potentially stronger if supported by long-term stability data
Container and device claims	Moderate where workflow benefits are substantial
Manufacturing process claims	Moderate, especially if difficult to design around
Method-of-use claims	Narrow and indication-dependent
Hospital preparation technology	Potentially strong commercial differentiation without broad drug exclusivity

A patent estate built solely around replacing sucrose with another carbohydrate is unlikely to create durable protection. Stronger opportunities combine composition with measurable performance, such as room-temperature stability, low particulate levels, rapid reconstitution, reduced adsorption, or extended in-use dating.

What excipient strategies can improve daptomycin products?

Ready-to-use liquid formulations

The highest-value opportunity is a stable liquid daptomycin product that removes pharmacy reconstitution. A ready-to-use presentation could be supplied in a flexible intravenous bag, dual-chamber container, syringe, or premixed vial.

The technical barriers include:

• Maintaining potency during extended liquid storage.
• Preventing aggregation and precipitation.
• Controlling pH drift.
• Limiting adsorption to polymeric containers.
• Managing oxidation and light sensitivity.
• Achieving acceptable particulate profiles.
• Establishing compatibility with common infusion materials.

A liquid product with a validated shelf life at refrigerated and controlled room temperatures could support outpatient infusion, hospital pharmacy automation, and emergency administration.

Improved lyophilized formulations

A new lyophilized formulation can target faster reconstitution, stronger cake integrity, lower residual moisture, and improved resistance to temperature excursions. Candidate excipient classes include alternative disaccharides, polyols, amino acids, buffers, and low-level surfactants.

Each addition increases regulatory and manufacturing complexity. Surfactants may reduce interfacial stress but can create questions around peroxide content, particle formation, and container compatibility. Buffers may improve pH control but can affect freeze-drying behavior and local tolerability. The commercial value must exceed the added development burden.

Reduced-volume and concentrated presentations

Hospitals may value a concentrated formulation that reduces infusion volume and preparation time. The principal development issues are osmolality, local tolerability, viscosity, precipitation risk, and compatibility with infusion devices.

A concentrated product is most attractive for fluid-restricted patients, outpatient treatment, and automated pharmacy compounding. It may qualify for differentiated method-of-use or formulation claims if the concentration and administration protocol provide a measurable clinical or operational advantage.

Longer in-use stability

Current labeling requires defined storage and use periods after reconstitution and dilution.[1] Extending those periods can reduce pharmacy waste and improve batch scheduling. A developer should test:

• Reconstituted vial stability.
• Diluted bag stability.
• Stability in PVC and polyolefin containers.
• Exposure to room temperature and refrigeration.
• Agitation and transport stress.
• Microbial risk in preservative-free systems.
• Compatibility with elastomers, needles, and transfer devices.

A longer in-use period can be commercially meaningful even without a new active ingredient.

Excipient and device combinations

The strongest commercial product may combine a modest excipient change with a proprietary transfer or administration system. Examples include:

• Closed-system vial adapters.
• Dual-chamber reconstitution containers.
• Premixed infusion bags.
• Pharmacy-ready bulk packages.
• Needle-free transfer systems.
• Single-use devices that reduce aerosolization and preparation steps.

Device claims can create a separate IP layer, although the product must satisfy combination-product requirements when the device is essential to administration.

What FDA regulatory pathways apply to new daptomycin products?

A conventional generic daptomycin injection generally follows the ANDA pathway if it matches the reference product in active ingredient, dosage form, strength, route, and relevant product characteristics.[2] A materially different liquid formulation, concentration, delivery system, or administration profile may require a 505(b)(2) application rather than an ANDA.

Development concept	Likely pathway
Same lyophilized dosage form and strength	ANDA
Same qualitative formulation with minor quantitative differences	Usually ANDA, subject to FDA requirements
Stable ready-to-use liquid	Potentially 505(b)(2)
New concentration or administration system	Potentially 505(b)(2)
New indication	505(b)(2) or supplemental strategy, depending on facts
New device-dependent presentation	ANDA or 505(b)(2), depending on product differences
Biosimilar application	Not applicable

The regulatory value of a 505(b)(2) product depends on whether the formulation difference provides a clear advantage. A product that merely changes sucrose concentration without improving stability, administration, safety, or adherence may not justify the additional regulatory and commercial burden.

What generic entry risks exist for CUBICIN?

Generic competition creates four principal risks:

1. Price erosion. Hospital systems and group purchasing organizations can shift volume to lower-cost suppliers.
2. Contracting pressure. Daptomycin is a mature injectable antibiotic with limited brand differentiation after generic entry.
3. Supply-chain substitution. Hospitals may approve multiple equivalent suppliers to reduce shortage exposure.
4. Formulation commoditization. Similar lyophilized products make the excipient profile less visible to purchasing departments.

The remaining commercial value is concentrated in supply reliability, vial size, reconstitution performance, shortage resilience, and total preparation cost. A product with a higher acquisition price can still compete if it lowers pharmacy labor, waste, administration time, or cold-chain expense.

What commercial opportunities remain for CUBICIN alternatives?

Hospital pharmacy efficiency

A ready-to-use or fast-reconstituting product can reduce preparation time and improve pharmacy throughput. The economic case should quantify labor minutes per dose, discarded doses, failed reconstitutions, and inventory complexity.

Outpatient parenteral antimicrobial therapy

Daptomycin is used in outpatient settings because it can support once-daily administration for appropriate infections. A product with extended refrigerated stability, room-temperature excursion tolerance, or simplified administration could compete in home infusion and ambulatory care.

Shortage and supply resilience

Generic sterile injectables remain exposed to manufacturing interruptions and facility concentration. A manufacturer with dual-site production, robust lyophilization capacity, and reliable vial supply can win institutional contracts even without a new excipient.

International markets

U.S. patent expiry does not eliminate geographic opportunities. Market access, national formularies, local manufacturing, procurement rules, and patent status differ across Europe, Japan, China, Latin America, and emerging markets. A region-specific formulation or packaging strategy may support registration where cold-chain infrastructure and pharmacy preparation practices differ.

Licensing and partnering

Potential licensing assets include:

• Stable liquid daptomycin technology.
• Premixed infusion systems.
• Lyophilization cycle technology.
• Low-particulate formulations.
• Polymer-container compatibility data.
• Closed-system transfer devices.
• Contract manufacturing capacity for sterile daptomycin.

Commercial partners are most likely to value technology that solves a documented hospital problem and has a credible regulatory path. A broad “new excipient” claim without comparative stability or workflow data has limited licensing value.

How does CUBICIN compare with competing injectable antibiotics?

CUBICIN competes with other hospital and outpatient therapies, including vancomycin, dalbavancin, oritavancin, linezolid, and generic daptomycin products. Its main operational advantage is once-daily dosing in appropriate patients. Its disadvantages include intravenous administration, laboratory monitoring requirements, cost pressure, and the absence of a protected branded formulation after generic entry.

Product category	Excipient opportunity	Commercial differentiation
Generic daptomycin lyophilized vial	Limited	Price, supply, reconstitution
Branded CUBICIN	Limited original formulation differentiation	Clinical familiarity and installed base
Ready-to-use daptomycin	High	Reduced pharmacy labor and waste
Dalbavancin injection	Moderate	Long dosing interval
Oritavancin injection	Moderate	Single-dose treatment in selected settings
Vancomycin injection	Moderate	Broad hospital use, but preparation burden
Linezolid injection	Low to moderate	Liquid presentation and administration convenience

The most realistic daptomycin opportunity is a hospital-efficiency product, not a conventional excipient me-too product.

Key Takeaways

• CUBICIN uses a simple lyophilized formulation with sucrose and sodium hydroxide.
• The core product and regulatory exclusivity have expired, and generic daptomycin competition is established.
• Broad excipient patent protection is unlikely to provide durable value without a defined technical performance advantage.
• Ready-to-use liquid formulations, improved in-use stability, concentrated presentations, and pharmacy-friendly devices offer the strongest commercial opportunities.
• An ANDA is appropriate for a substantially equivalent generic; materially different presentations may require a 505(b)(2) application.
• Biosimilar competition is irrelevant because daptomycin is a synthetic small molecule, not a biologic.
• The best remaining sources of value are lower preparation cost, reduced waste, supply reliability, outpatient usability, and differentiated packaging.
• Patent strategies should combine formulation, manufacturing, container, device, and method-of-use claims where legally supportable.

FAQs About CUBICIN Excipients and Commercial Strategy

Does CUBICIN contain polysorbate 80?

No. FDA labeling identifies sucrose and sodium hydroxide as inactive ingredients for CUBICIN. The approved formulation does not list polysorbate 80.[1]

Can a generic manufacturer use a different excipient from CUBICIN?

Potentially. An ANDA product must satisfy FDA requirements for pharmaceutical equivalence, quality, safety, and performance. A different excipient may be acceptable if it does not create an unapproved safety or performance difference.

Is daptomycin eligible for a biosimilar application?

No. Daptomycin is a chemically synthesized small-molecule antibacterial. Generic versions use the ANDA framework rather than the biosimilar pathway.

What is the most valuable new CUBICIN formulation?

A stable ready-to-use liquid or premixed infusion product has the clearest commercial rationale because it can reduce pharmacy preparation, waste, and administration burden.

Can a new daptomycin excipient formulation obtain patent protection?

Yes, if the formulation satisfies patentability requirements and provides claims that are novel, nonobvious, enabled, and commercially meaningful. Stronger claims typically require defined composition ranges linked to measurable stability or administration advantages.

References

1. U.S. Food and Drug Administration. (2023). CUBICIN (daptomycin for injection) prescribing information. Merck & Co., Inc. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, CUBICIN NDA 021572. https://www.accessdata.fda.gov/scripts/cder/daf/
4. Merck & Co., Inc. (2016). 2015 annual report. https://www.merck.com/investor-relations/financial-information/annual-reports/
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm